Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V 617 F mutation of Jak 2
暂无分享,去创建一个
M. Cazzola | R. Kralovics | F. Passamonti | A. Buser | Soon-Siong Teo | R. Tiedt | A. Tichelli | R. Skoda | D. Pietra | M. Brutsche
[1] Stefan N Constantinescu,et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. , 2005, Nature.
[2] Mario Cazzola,et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.
[3] T. Maiwald,et al. Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF‐E2 , 2005, British journal of haematology.
[4] Sandra A. Moore,et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.
[5] P. Campbell,et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.
[6] M. Cazzola,et al. Clinical significance of neutrophil CD177 mRNA expression in Ph‐negative chronic myeloproliferative disorders , 2004, British journal of haematology.
[7] Ulrich Schlecht,et al. Expression profiling of mammalian male meiosis and gametogenesis identifies novel candidate genes for roles in the regulation of fertility. , 2003, Molecular biology of the cell.
[8] H. Heimpel,et al. Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. , 2003, Blood.
[9] R. Kralovics,et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. , 2003, Blood.
[10] C. Langford,et al. Gene expression profiling in polycythemia vera using cDNA microarray technology. , 2003, Cancer research.
[11] J. Jelinek,et al. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. , 2003, Blood.
[12] N. Harris,et al. The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.
[13] Ryoiti Kiyama,et al. A Novel Ankyrin Repeat-containing Gene (Kank) Located at 9p24 Is a Growth Suppressor of Renal Cell Carcinoma* , 2002, The Journal of Biological Chemistry.
[14] D. Aaronson,et al. A Road Map for Those Who Don't Know JAK-STAT , 2002, Science.
[15] A. Gurney,et al. A Novel Type I Cytokine Receptor Is Expressed on Monocytes, Signals Proliferation, and Activates STAT-3 and STAT-5* , 2002, The Journal of Biological Chemistry.
[16] R. Kralovics,et al. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. , 2002, Experimental hematology.
[17] T. Barbui,et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera , 2000 .
[18] M. Lübbert,et al. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. , 2000, Blood.
[19] T. Pearson. Evaluation of diagnostic criteria in polycythemia vera. , 2001, Seminars in hematology.
[20] S. Murphy. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. , 1999, Seminars in hematology.